A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia

@article{George2007AS2,
  title={A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia},
  author={M. George and Christine E. Molnar and E. Grenesko and B. Anderson and Q. Mu and Kevin Johnson and Z. Nahas and M. Knable and P. Fernandes and Jorge J Juncos and Xuemei Huang and D. E. Nichols and R. Mailman},
  journal={Schizophrenia Research},
  year={2007},
  volume={93},
  pages={42-50}
}
The potential of dopamine D(1) receptor agonists to have beneficial effects on cognitive function has been suggested by a body of preclinical evidence. We now report the use of dihydrexidine (DAR-0100), the first full D(1) agonist, in a pilot study assessing single low dose safety and tolerability in patients with schizophrenia. A within-subject cross-over design was used in 20 adults (18-65 years) with SCID-IV diagnosed schizophrenia. Subjects were outpatients with a moderate level of residual… Expand
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia
TLDR
Analysis revealed that dihydrexidine induced a significant increase in both prefrontal and non-prefrontal perfusion compared to placebo, consistent with the short pharmacokinetic half-life of diHydrexidine. Expand
Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder
TLDR
Findings lend further clinical support to the potential of D1 receptor agonists to treat schizophrenia-spectrum working memory impairments, and suggest a need for further studies with larger group sizes, serum DAR-0100A levels, and a more comprehensive neuropsychological battery. Expand
A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia
TLDR
It is suggested that low doses of D1 agonists that do not result in measureable occupancy of the D1R do not reliably improve cognition in SCZ, unlike the observations in NHP. Expand
A proof-of-principle study of the effect of combined haloperidol and levodopa administration on working memory-related brain activation in humans
TLDR
This preliminary study provides initial evidence for combined L-dopa/haloperidol modulation in cognition-related brain areas and networks, which is relevant for the treatment of cognitive impairments in mental illness. Expand
Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies
TLDR
The pharmacokinetics of ASP4345 suggest that single daily dosing is appropriate for ASP 4345, and the concentration of AS4345 in cerebrospinal fluid compared to free drug concentrations in plasma provides evidence of penetration ofAS4345 into the brain. Expand
The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
TLDR
PF-06412562 was tolerated in advPD patients and provides the feasibility for future safety and efficacy studies in this population with unmet needs. Expand
Multiple dopamine receptors mediate the discriminative stimulus effects of dihydrexidine in rats
TLDR
Determinations of activity at second messenger systems revealed that DHX functioned as a full agonist at D3 receptors and a partial agonists at D2 receptors in vitro, suggesting that both D1 and D2/D3 receptors mediate the discriminative stimulus effects of DHX. Expand
Characterization of in vivo Pharmacokinetic Properties of the Dopamine D1 Receptor Agonist DAR-0100A in Nonhuman Primates Using PET with [11C] NNC112 and [11C] Raclopride
TLDR
Data suggest that at doses likely to be administered to patients, occupancy will not be detectable with [11C] NNC112 PET and binding of DAR-0100A to D2 will be negligible, the first demonstration with PET of a significant occupancy by a full D1 agonist in vivo. Expand
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
TLDR
An update and critical review of the pharmacology and clinical profiles of current antipsychotic drugs and drugs acting on novel targets with potential to be therapeutic agents in the future is provided. Expand
Neurobiological Background for the Development of New Drugs in Schizophrenia
TLDR
Research in the antipsychotics field has developed also by exploring pathways that are beyond the spectrum of clozapine, and among the most promising mechanisms are those based on the glutamatergic hypothesis of schizophrenia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia
TLDR
Analysis revealed that dihydrexidine induced a significant increase in both prefrontal and non-prefrontal perfusion compared to placebo, consistent with the short pharmacokinetic half-life of diHydrexidine. Expand
Effects of the Full Dopamine Dl Receptor Agonist Dihydrexidine in Parkinson's Disease
TLDR
Preliminary data suggest that dihydrexidine has a marginal therapeutic window for providing an anti-parkinsonian effect, although it remains uncertain how much of this effect is attributable to pure Dl receptor stimulation. Expand
Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patients
TLDR
The result of the study does not support the prediction that selective D1 dopamine receptor antagonism will produce antipsychotic effects in schizophrenia. Expand
A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex.
TLDR
Chronic treatment with clozapine, haloperidol, and remoxipride up-regulates D2 receptors in specific cortical areas of the rhesus monkey frontal, parietal, temporal, and occipital lobes, raising the possibility that down-regulation of D1 receptors in prefrontal and temporal cortex may be an important component of the therapeutic response to neuroleptic drugs. Expand
ABT‐431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease
TLDR
ABT‐431 is the first dopamine D1 receptor agonist to demonstrate a full antiparkinsonian effect in patients with Parkinson's disease, and these preliminary findings suggest that it may exhibit a reduced tendency to provoke dyskinesia. Expand
The D1 Agonist Dihydrexidine Releases Acetylcholine and Improves Cognition in Rats
TLDR
Results provided support for the hypothesis that DHX improves cognitive performance as a consequence of ACh release in relevant brain regions, and D1 agonists may have novel therapeutic potential in the treatment of dementia. Expand
Dihydrexidine--the first full dopamine D1 receptor agonist.
TLDR
An updated overview of the pharmacology of dihydrexidine is provided and possible clinical utility of dopamine D(1) receptor agonists in various central nervous system disorders is discussed. Expand
Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys
TLDR
Monkeys exposed to low doses of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine develop difficulty in performing a previously learned delayed response (DR) task and the similarities between this primate model and the cognitive/behavioral deficits associated with early Parkinson's disease and attention deficit hyperactivity disorder suggest this may be a useful model for testing hypotheses concerning the pharmacological treatment of these disorders. Expand
Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs.
TLDR
A reduction in the levels of prefrontal cortical dopamine receptors of the D1 class may be an obligatory consequence of D2 receptor antagonism and thus may be a pharmacological property of antipsychotic drugs. Expand
Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia
TLDR
The results of the present study do not support the hypothesis that D1-dopamine antagonists are clinically effective antipsychotics in schizophrenia, considering the fact that SCH 39166 had no effect on positive symptoms. Expand
...
1
2
3
4
...